COMP <GO>
ACRS vs CRMD // DIVIDEND YIELD & FCF PAYOUT SAFETY
Aclaris Therapeutics Inc. (NASDAQ) VS. CorMedix Inc. (NASDAQ) • 15-METRIC TALLY: ACRS 1
— CRMD 8
■ METRIC PARITY
LAST: $3.99 (+0.76%) • MKT CAP: $587.3M
dividend-safety
0.00%
LAST: $7.64 (-6.83%) • MKT CAP: $595.5M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRS VS. CRMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACRS | CRMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | 88.50% | -15.20 | CRMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 45.50% | -80.50 | CRMD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 3.0x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.04% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 48.20% | -108.20 | CRMD | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 52.30% | -112.30 | CRMD | /net-margins <GO> |
| Revenue Growth (YoY) | -58.20% | 180.00% | -238.20 | CRMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 1.81 | -1.61 | CRMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | CRMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 25.3 | +20.21 | ACRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 3.5x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $587.3M | $595.5M | -$8.2M | CRMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACRS REV | CRMD REV | ACRS GROSS % | CRMD GROSS % | ACRS FCF | CRMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.8M | $311.7M | 73.3% | 88.5% | -$47.2M | $172.8M |
| FY 2024 | $18.7M | $43.5M | 85.1% | 92.7% | -$20.2M | -$50.7M |
| FY 2023 | $31.2M | $0 | — | — | -$78.3M | -$38.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRS // BETA —
CRMD // BETA —